OBI Pharma Showcases Proprietary ADC Platform GlycOBI® in China
Drawing Strong Industry Interest

OBI Pharma (4174.TWO) Chief Scientific Officer, Dr. Ming-Tain Lai, delivered a presentation today (2/20) at the 2025 ADC Drug Development Conference in Suzhou, China. OBI Pharma’s proprietary site-specific glycan conjugation platform, GlycOBI®, garnered strong interest from attendees and industry professionals for its plug-and-play adaptability to any antibody and its development potential.

HOMEWhat’s NewNewsOBI Pharma Showcases Proprietary ADC Platform GlycOBI® in China Drawing Strong Industry Interest

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2025.Feb.19

Invited to the 2025 Healthcare Conference in Taipei, Dr. Heidi Wang engaged in discussions on Regulatory Landscape and International Partnerships in Pharma and Diagnostics

2025.Mar.02

OBI Pharma's GlycOBI® Platform Gains Attention at Nanjing Summit Optimized Process Design and CMC: Key to Next-Generation ADC Development